Cytotoxic actin-targeting compounds
AssigneeQueen's University at Kingston
InventorsRebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
Life of this patent
Estimating the term…
Abstract
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
Claims21
A compound of Formula (1),
- wherein
- R1 is independently —C(═O)R, —C(OR)(R)(R), —C(═O)NR2R3, —S(O2)NR, —P(═O)(OR)2, aliphatic moiety or aryl moiety, and
- R, R2, and R3 are independently a substituted or unsubstituted aliphatic moiety, or a substituted or unsubstituted aryl moiety, that optionally includes one or more heteroatoms.
A compound selected from compound 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 11, 12, MA-02-058, MA-02-047, MA-02-044, or MA-02-046 as shown below
A pharmaceutical composition comprising compound 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 11, 12, MA-02-058, MA-02-047, MA-02-044, MA-02-046, or a pharmaceutically acceptable salt thereof, and further comprising a pharmaceutically acceptable vehicle
Dependencies are inferred from the claim text.